Jeanne Shen

Jeanne Shen

Auto-generated profile, based on publicly available information

Jeanne Shen

Department of Pathology, Stanford School of Medicine, Stanford, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in The Lancet Oncology
Verified
Journal Article
Closed access
RYRikiya Yamashita
Rikiya Yamashita
JLJin Long
Jin Long
TLTeri Longacre
Teri Longacre
LPLan Peng
Lan Peng
GBGerald Berry
Gerald Berry
JSJeanne Shen
Jeanne Shen

20 June 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
WBWinston R. Becker
Winston R. Becker
SNStephanie A. Nevins
Stephanie A. Nevins
DCDerek C. Chen
Derek C. Chen
RCRoxanne Chiu
Roxanne Chiu
AHAaron M. Horning
Aaron M. Horning
WGWilliam J. Greenleaf
William J. Greenleaf
To chart cell composition and cell state changes that occur during the transformation of healthy colon to precancerous adenomas to colorectal cancer (CRC), we generated single-cell chromatin accessibility profiles and single-cell transcriptomes from 1,000 to 10,000 cells per sample for 48 polyps, 27 normal tissues and 6 CRCs collected from patients with or without germline APC mutations. A large fraction of polyp and CRC cells exhibit a stem-like phenotype, and we define a continuum of epigenetic and transcriptional changes occurring in these stem-like cells as they progress from homeostasis to CRC. Advanced polyps contain increasing numbers of stem-like cells, regulatory T cells and a subtype of pre-cancer-associated fibroblasts. In the cancerous state, we observe T cell exhaustion, RUNX1-regulated cancer-associated fibroblasts and increasing accessibility associated with HNF4A motifs in epithelia. DNA methylation changes in sporadic CRC are strongly anti-correlated with accessibility changes along this continuum, further identifying regulatory markers for molecular staging of polyps.

26 February 2020 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
AKAmirhossein Kiani
Amirhossein Kiani
BUBora Uyumazturk
Bora Uyumazturk
PRPranav Rajpurkar
Pranav Rajpurkar
AWAlex Wang
Alex Wang
RGRebecca Gao
Rebecca Gao
JSJeanne Shen
Jeanne Shen
Artificial intelligence (AI) algorithms continue to rival human performance on a variety of clinical tasks, while their actual impact on human diagnosticians, when incorporated into clinical workflows, remains relatively unexplored. In this study, we developed a deep learning-based assistant to help pathologists differentiate between two subtypes of primary liver cancer, hepatocellular carcinoma and cholangiocarcinoma, on hematoxylin and eosin-stained whole-slide images (WSI), and evaluated its effect on the diagnostic performance of 11 pathologists with varying levels of expertise. Our model achieved accuracies of 0.885 on a validation set of 26 WSI, and 0.842 on an independent test set of 80 WSI. Although use of the assistant did not change the mean accuracy of the 11 pathologists (p = 0.184, OR = 1.281), it significantly improved the accuracy (p = 0.045, OR = 1.499) of a subset of nine pathologists who fell within well-defined experience levels (GI subspecialists, non-GI subspecialists, and trainees). In the assisted state, model accuracy significantly impacted the diagnostic decisions of all 11 pathologists. As expected, when the model’s prediction was correct, assistance significantly improved accuracy (p = 0.000, OR = 4.289), whereas when the model’s prediction was incorrect, assistance significantly decreased accuracy (p = 0.000, OR = 0.253), with both effects holding across all pathologist experience levels and case difficulty levels. Our results highlight the challenges of translating AI models into the clinical setting, and emphasize the importance of taking into account potential unintended negative consequences of model assistance when designing and testing medical AI-assistance tools.

27 March 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MMMagdalena Matusiak
Magdalena Matusiak
JHJohn W. Hickey
John W. Hickey
DIDavid G.P. van Ijzendoorn
David G.P. van Ijzendoorn
GLGuolan Lu
Guolan Lu
LKLukasz Kidziński
Lukasz Kidziński
MRMatt van de Rijn
Matt van de Rijn
Tumor-associated macrophages are transcriptionally heterogeneous, but the spatial distribution and cell interactions that shape macrophage tissue roles remain poorly characterized. Here, we spatially resolve five distinct human macrophage populations in normal and malignant human breast and colon tissue and reveal their cellular associations. This spatial map reveals that distinct macrophage populations reside in spatially segregated micro-environmental niches with conserved cellular compositions that are repeated across healthy and diseased tissue. We show that IL4I1+ macrophages phagocytose dying cells in areas with high cell turnover and predict good outcome in colon cancer. In contrast, SPP1+ macrophages are enriched in hypoxic and necrotic tumor regions and portend worse outcome in colon cancer. A subset of FOLR2+ macrophages is embedded in plasma cell niches. NLRP3+ macrophages co-localize with neutrophils and activate an inflammasome in tumors. Our findings indicate that a limited number of unique human macrophage niches function as fundamental building blocks in tissue. Significance: This work broadens our understanding of the distinct roles different macrophage populations may exert on cancer growth and reveals potential predictive markers and macrophage population-specific therapy targets.

4 January 2023 in EBioMedicine
Verified
Journal Article
Open access
MBM. Alvaro Berbís
M. Alvaro Berbís
DMDavid S. McClintock
David S. McClintock
ABAndrey Bychkov
Andrey Bychkov
JLJeroen Van der Laak
Jeroen Van der Laak
LPLiron Pantanowitz
Liron Pantanowitz
JSJeanne Shen
Jeanne Shen
Artificial intelligence (AI) is rapidly fuelling a fundamental transformation in the practice of pathology. However, clinical integration remains challenging, with no AI algorithms to date in routine adoption within typical anatomic pathology (AP) laboratories. This survey gathered current expert perspectives and expectations regarding the role of AI in AP from those with first-hand computational pathology and AI experience. Perspectives were solicited using the Delphi method from 24 subject matter experts between December 2020 and February 2021 regarding the anticipated role of AI in pathology by the year 2030. The study consisted of three consecutive rounds: 1) an open-ended, free response questionnaire generating a list of survey items; 2) a Likert-scale survey scored by experts and analysed for consensus; and 3) a repeat survey of items not reaching consensus to obtain further expert consensus. Consensus opinions were reached on 141 of 180 survey items (78.3%). Experts agreed that AI would be routinely and impactfully used within AP laboratory and pathologist clinical workflows by 2030. High consensus was reached on 100 items across nine categories encompassing the impact of AI on (1) pathology key performance indicators (KPIs) and (2) the pathology workforce and specific tasks performed by (3) pathologists and (4) AP lab technicians, as well as (5) specific AI applications and their likelihood of routine use by 2030, (6) AI's role in integrated diagnostics, (7) pathology tasks likely to be fully automated using AI, and (8) regulatory/legal and (9) ethical aspects of AI integration in pathology. This systematic consensus study details the expected short-to-mid-term impact of AI on pathology practice. These findings provide timely and relevant information regarding future care delivery in pathology and raise key practical, ethical, and legal challenges that must be addressed prior to AI's successful clinical implementation. No specific funding was provided for this study.

14 December 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJulien Calderaro
Julien Calderaro
NLNarmin Ghaffari Laleh
Narmin Ghaffari Laleh
QZQinghe Zeng
Qinghe Zeng
PMPascale Maille
Pascale Maille
LFLoetitia Favre
Loetitia Favre
JKJakob Nikolas Kather
Jakob Nikolas Kather
Primary liver cancer arises either from hepatocytic or biliary lineage cells, giving rise to hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICCA). Combined hepatocellular- cholangiocarcinomas (cHCC-CCA) exhibit equivocal or mixed features of both, causing diagnostic uncertainty and difficulty in determining proper management. Here, we perform a comprehensive deep learning-based phenotyping of multiple cohorts of patients. We show that deep learning can reproduce the diagnosis of HCC vs. CCA with a high performance. We analyze a series of 405 cHCC-CCA patients and demonstrate that the model can reclassify the tumors as HCC or ICCA, and that the predictions are consistent with clinical outcomes, genetic alterations and in situ spatial gene expression profiling. This type of approach could improve treatment decisions and ultimately clinical outcome for patients with rare and biphenotypic cancers such as cHCC-CCA.